AXT Insiders Cash Out $78.8M While Analysts Cling to Bullish Targets — and the Share Price Is Caught in Between

AXT insiders sold $78.8M in shares over 12 months, no buys, despite strong AI-driven demand and a $100M backlog through 2027.

The disconnect at AXT has rarely been sharper. On one side sits a business firing on all cylinders: a landmark supply agreement with Lumentum, prepayments stacking up, and analysts lifting price targets. On the other, a steady stream of insider selling that has now reached $78.8 million over the past twelve months — with not a single insider purchase to offset it. That gap between what executives do with their own money and what Wall Street says about the stock is the central tension investors must weigh.

The insider activity is hard to dismiss as noise. Director Leonard LeBlanc sold 4,000 shares at $96.07 on August 17, following a 2,000-share sale at $88.315 on August 7. Two more transactions were recorded on August 19, according to company disclosures. None of these trades were executed under a pre-arranged 10b5-1 plan, which means the timing was discretionary — a detail that gives the selling a more deliberate character than automated divestments would.

The Bull Case: A Backlog That Stretches to 2027

The fundamental picture, to be fair, is genuinely robust. The Lumentum Operations agreement, signed in late July, locks in indium phosphide wafer substrate supply through December 2031 and brings total prepayments of $87 million, to be applied as delivery credits. That's on top of long-term supply contracts with Casella and Coherent, which carry advance payments of $22.3 million and $25.4 million respectively. The order book now sits comfortably above $100 million and extends into 2027.

The strategic pivot toward indium phosphide — a critical material for optical components in AI data centers — has reshaped the company's profile. Northland Capital Markets raised its price target to $125 in August with an Outperform rating, reflecting the growing conviction among some houses that the momentum is real.

The Bear Case: Valuation, Margins, and Regulatory Hurdles

Yet the stock has been anything but stable. After a spectacular rally, shares fell 12 percent on Friday to €50.76, capping a two-day slide of roughly 12.4 percent that began with sector-wide profit-taking across the indium phosphide supply chain. Peers including Lumentum, Coherent, and Applied Optoelectronics dropped between five and six percent over the same stretch.

The sell-side has turned more cautious. A Seeking Alpha contributor operating under the pseudonym "Bears of Wall Street" issued a Sell rating over the weekend, arguing the risk-reward has deteriorated after the massive run-up in market capitalization. The current valuation, the analyst contended, assumes "flawless execution" on both ramping indium phosphide capacity and securing Chinese export approvals — neither of which is guaranteed. Separate reports on Friday pointed to another downgrade that questioned the sustainability of the 45 percent gross margin posted in the second quarter.

Export licensing has been a recurring headache for AXT, and renewed doubts about approvals for key shipments have added to investor anxiety. The chart has turned ugly too: the stock now trades 9.6 percent below its 50-day moving average of €56.13, a technical warning that has amplified the unease.

A Structural Wildcard: The China Subsidiary's Pivot

Beyond the trading noise sits a strategic development that deserves more attention than it has received. Beijing Tongmei Xtal Technology, AXT's Chinese subsidiary, has abandoned its planned IPO on Shanghai's STAR Market and is now targeting a listing on the Hong Kong Exchange — a process that could take roughly a year. The shift introduces fresh uncertainty into the parent company's valuation, particularly given the vague timeline.

There's also the matter of perception. The launch of a leveraged inverse ETF on AXT by Tradr signals how far the stock has traveled from its roots as a straightforward semiconductor supplier. It is now a speculative vehicle, traded as much on momentum and narrative as on fundamentals.

The Management Counter-Offensive

Management, for its part, is pressing the growth story. The company presented at the Needham Semiconductor Conference on August 20, hammering the AI-driven demand for indium phosphide substrates. Additional appearances are scheduled for September 10 at a B. Riley Securities conference and September 21-22 at the Morgan Stanley Asia Best Corporate Day.

Whether those appearances can soothe concerns about margins and export approvals remains an open question. The coming weeks will test whether the company can bridge the gap between its operational strength and the persistent skepticism — both from insiders who keep selling and from analysts who see more downside than upside at current levels.